The histiocytic marker PG-M1 is helpful in differentiating histiocytes and histiocytic tumors from melanomas.
Previous studies have shown that immunohistochemical stains for histiocytes are immunoreactive for melanomas. Accordingly, their value in differentiating histiocytes and histiocytic lesions from melanomas was questioned. PG-M1, the most specific histiocytic marker, was not evaluated in these studies. Our aims were to assess the reactivity of PG-M1 with a series of primary cutaneous and metastatic melanomas and to establish the potential usefulness of this antibody in the differentiation between histiocytes and histiocytic tumors and melanomas. PG-M1 staining was performed in 50 primary cutaneous and metastatic melanomas. For comparison, additional sections were stained with KP-1 and lysozyme (commonly used as histiocytic markers) and with S-100 and HMB-45 (commonly used as melanoma markers). The intensity (1+, 2+) and extent (1+ to 4+) were recorded semiquantitatively. PG-M1 stained weakly (1+) and focally (2+) only four cases of melanoma (8%). In contrast, histiocytes were strongly reactive for PG-M1 in all cases, being readily differentiated from melanoma cells including the positive cases. KP-1 stained melanoma cells in 44 cases (88%), lysozyme in 11 cases (22%), S-100 in 50 cases (100%), and HMB-45 in 48 cases (96%). No changes were found after restaining of selected KP-1 and lysozyme positive melanomas using an endogenous avidin/biotin blocking kit. PG-M1 is helpful in discriminating histiocytes and histiocytic lesions from melanoma cells. We recommend its inclusion in any antibody panel put together to distinguish between them.
Groisman
Gabriel M
GM
Hillel-Yaffe Medical Center, Hadera, Israel. groisman@hillel-yaffe.health.gov.il
Amar
Mary
M
Schäfer
Ion
I
D015703:Antigens, CD / Q000378:metabolism*; D015214:Antigens, Differentiation, Myelomonocytic / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000378:metabolism; D003937:Diagnosis, Differential; D006644:Histiocytes / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008545:Melanoma / Q000175:diagnosis* / Q000276:immunology* / Q000473:pathology / Q000556:secondary; D009113:Muramidase / Q000378:metabolism; D018218:Neoplasms, Fibrous Tissue / Q000175:diagnosis* / Q000276:immunology* / Q000473:pathology; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000276:immunology* / Q000473:pathology; D000097382:CD68 Molecule
D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D014408:Biomarkers, Tumor; D009113:Muramidase; C067980:CD68 antigen, human; D000097382:CD68 Molecule